93% OF TROGARZO® PATIENTS SURVEYED RECOMMEND TROGARZO® TO OTHER PATIENTS WITH HIV-1

Male patient expressing happiness and joy resulting from lowering his HIV viral load

LOWER YOUR VIRAL LOAD AND MAKE UNDETECTABLE* A POSSIBILITY AGAIN

Imagine regaining viral suppression, even if other HIV-1 treatments have failed you. TROGARZO® (ibalizumab-uiyk) is a breakthrough in HIV-1 treatment, the first long-acting antiviral, designed specifically for those with a history of prior virologic failures.1,2

IS TROGARZO® RIGHT FOR YOU?

*Undetectable viral load is defined as fewer than 50 copies of HIV per mL of blood.

DON’T JUST TAKE OUR WORD FOR IT

REAL PATIENTS TAKING TROGARZO® GAVE EXTREMELY POSITIVE RATINGS*

The objective of this survey was to better understand experience with TROGARZO® from a patient perspective. Thirty patients taking TROGARZO® were surveyed online between December 2020 and March 2021.

87%

VERY SATISFIED with TROGARZO® infusion experience

87%

Having a 2-week touch point with their HCP was a POSITIVE EXPERIENCE

80%

Having a 2-week touch point with their HCP helped them adhere to their other HIV Medications

“If you have taken other drugs with nominal results, I strongly suggest TROGARZO® if you are looking to lower your viral load toward becoming undetectable.”

- A real TROGARZO® patient

93% OF TROGARZO® PATIENTS SURVEYED RECOMMEND TROGARZO® TO OTHER PATIENTS WITH HIV-1

Is Trogarzo® right for you?

FIND OUT IF TROGARZO® IS RIGHT FOR YOU

ARE YOU GETTING THE MOST FROM YOUR HIV-1 TREATMENT?

Are you having any challenges taking your current HIV medications?

YES
NO
Video of patient describing the experience of living with HIV

See Nelson’s
TROGARZO® experience

This is the experience of one patient and may not be representative of all TROGARZO® patients.


Download the Discussion Guide to help you start the conversation with your healthcare provider about TROGARZO®. Ensure you are getting th emost from your HIV-1 treatment by asking the right questions.

DOWNLOAD PATIENT GUIDE

BRINGING VIRAL SUPPRESSION BACK WITHIN REACH

If you have experienced treatment failures, it may feel like getting your viral load back to undetectable levels is out of reach.

Imagine regaining viral suppression,

even if other treatments have failed you.

To combat HIV-1 when treatment fails, a regimen should be modified as soon as possible to avoid further resistance. The most effective HIV-1 treatment regimen is one that combines 3 active antiretroviral medicines. An active antiretroviral medicine could be a new type you didn’t try before.

LIGHTEN THE VIRAL LOAD

In a clinical study, TROGARZO® was proven to have a significant and long-lasting impact on the amount HIV-1 in the body, reducing or “lightening” viral load.

83% of patients

were able to

reduce their HIV-1 viral load

after receiving a single dose of TROGARZO®.

Also, studies showed that patients who reached undetectable were able to remain undetectable over time. TROGARZO® does not interact with other drugs, so you can take it with other medications you may be taking. Be sure to discuss other medications you may be taking with your healthcare provider before taking TROGARZO®.

A BREAKTHROUGH IN HIV-1 TREATMENT.

TROGARZO® is a medicine that’s used in combination with other antiretroviral medicines to treat HIV-1 infection in adults who:

Trogarzo is for patients who have used several HIV-1 drugs in the past

Have been on different HIV-1 treatment regimens in the past, and

Plus who have HIV-1 that is resistant to other HIV-1 medications

Have HIV-1 that is resistant to antiretroviral medicines, and

And who are on a HIV-treatment regimen that is failing

Are currently on an HIV-1 treatment regimen that is failing

THE FIRST LONG‑ACTING ANTIVIRAL AGAINST HIV‑1

TROGARZO® works differently. Unlike antiretroviral medicines that aim to prevent HIV-1 from multiplying inside the immune system’s T-cells, it is a biologic - an antibody bioengineered specifically to protect your T-cells from the virus. TROGARZO® binds to the T-cell’s surface to block HIV-1 from entering.

This can help protect the T-cell and reduce or “lighten” your viral load.

THE FIRST LONG‑ACTING ANTIVIRAL AGAINST HIV‑1

TROGARZO® works differently. Unlike antiretroviral medicines that aim to prevent HIV-1 from multiplying inside the immune system’s T-cells, it is a biologic - an antibody bioengineered specifically to protect your T-cells from the virus. TROGARZO® binds to the T-cell’s surface to block HIV-1 from entering.

This can help protect the T-cell and reduce or “lighten” your viral load.

TAKEN EVERY TWO WEEKS

TROGARZO® is not a daily pill. It’s an intravenous (IV) infusion given over 15 to 30 minutes every 2 weeks. Infusion appointments can be a great time to ask any questions you may have about your treatment, or simply keep in touch with your care provider.

Trogarzo is given once every 2 weeks

Given once
every 2 weeks

Appointments arranged by patient care coordinator

Appointments arranged by your personal Patient Care Coordinator

Trogarzo is administered by healthcare providers in their clinics or offices, or at your home

Given by a healthcare provider at home, an infusion center or healthcare provider’s office

Patient program helps patients with ongoing support throughout treatment

Thinking about how to afford your treatment?

Don’t worry, TROGARZO® is widely covered by all commercial and government insurance plans, including ADAP. Commercially insured patients may be eligible for co-pay assistance and may pay as little as $0.

From appointment reminders to insurance coverage assistance, and anything in between, THERA patient support® is here to help.

FOR MORE INFORMATION

*Required fields.

I would like more information about:

By providing the above information, you agree to allow Theratechnologies Inc. to provide you with information relating to Theratechnologies' products.
The information you submit will be governed by our Privacy Policy.

If you have any questions, call the THERA patient support® program at 1-833-23-THERA (1-833-238-4372).
Monday-Friday, 8:30AM-8:00PM ET.

References: 1. TROGARZO® Prescribing Information. Theratechnologies Inc. April 2021. 2. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV, October 2018.


Download the TROGARZO® Patient Information, which includes complete product information.

IMPORTANT SAFETY INFORMATION

Do not receive TROGARZO® if you have had an allergic reaction to TROGARZO® or any of the ingredients in TROGARZO®.

TROGARZO® can cause serious side effects, including:

  • Allergic reactions. TROGARZO® can cause allergic reactions, including serious reactions, during and after infusion. Tell your healthcare provider or nurse, or get medical help right away if you get any of the following symptoms of an allergic reaction:

  • Allergic reactions. TROGARZO® can cause allergic reactions, including serious reactions, during and after infusion. Tell your healthcare provider or nurse, or get medical help right away if you get any of the following symptoms of an allergic reaction:

  • trouble breathing

  • cough

  • swelling in your throat

  • hot flush

  • wheezing

  • nausea

  • chest pain

  • vomiting

  • chest tightness

  • Changes in your immune system (Immune Reconstitution Inflammatory Syndrome) can happen when you start taking HIV-1 medicines. Your immune system might get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your health care provider right away if you start having new symptoms after receiving TROGARZO®.

The most common side effects of TROGARZO® include diarrhea, dizziness, nausea, and rash. These are not all the possible side effects of TROGARZO®.

Before you receive TROGARZO®, tell your healthcare provider about all of your medical conditions, including if you are:

  • Pregnant or plan to become pregnant. It is not known if TROGARZO® may harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with TROGARZO®.

  • Breastfeeding or plan to breastfeed. You should not breastfeed if you have HIV-1 because of the risk of passing HIV-1 to your baby. Do not breastfeed if you are receiving TROGARZO® as it is not known if TROGARZO® passes into breast milk. Talk with your healthcare provider about the best way to feed your baby during treatment with TROGARZO®.

Also, tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

For more information or medical advice about side effects, ask your healthcare provider. You may report side effects to the FDA at 1-800-FDA-1088 or the THERA patient support® at 1-833-23THERA (1-833-238-4372).

WHAT IS TROGARZO®?

TROGARZO® (ibalizumab-uiyk) is a prescription medicine that is used with other antiretroviral medicines to treat Human Immunodeficiency Virus-1 (HIV-1) infection in adults who:

  • have received anti-HIV-1 regimens in the past, and

  • have HIV-1 virus that is resistant to antiretroviral medicines, and

  • who are failing their current antiretroviral therapy

It is not known if TROGARZO® is safe and effective in children.

Please see full Prescribing Information for TROGARZO®.